国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
7期
906-908
,共3页
自体血循管%预防%血透%首次使用综合征%疗效分析
自體血循管%預防%血透%首次使用綜閤徵%療效分析
자체혈순관%예방%혈투%수차사용종합정%료효분석
Autologous blood circulation pipe%Prevention%Hemodialysis%First-use syndrome (FUS)%Efficacy analysis
目的 研究使用自体血循管预防血透病人首次使用综合征的可行性,提高透析质量、减轻患者痛苦及医疗费用.方法 将维持性血液透析的患者156人共1158例次,按照透析时间分为对照组和实验组.对照组按常规血透流程操作,实验组在对新的透析器和管路进行常规预冲后使用患者自体血密闭式循管10 ～ 15 min,对两组患者血透过程中首次使用综合征(First-useSyndrome,FUS)发生率及体外凝血发生率进行对比.结果 对照组在560例次透析治疗的病人中,共发生FUS 23例次(4.11％),而实验组在598例次透析治疗的病人中,共发生FUS 5例次(0.84％).FUS发生率实验组明显低于对照组,两组比较差异有统计学意义(P＜0.01),而体外凝血发生率则两组无明显改变,差异无统计学意义(P＞0.05).结论 使用患者自体血循管能有效预防血透病人血透过程中首次使用综合征的发生,且不增加出血及体外凝血现象风险.
目的 研究使用自體血循管預防血透病人首次使用綜閤徵的可行性,提高透析質量、減輕患者痛苦及醫療費用.方法 將維持性血液透析的患者156人共1158例次,按照透析時間分為對照組和實驗組.對照組按常規血透流程操作,實驗組在對新的透析器和管路進行常規預遲後使用患者自體血密閉式循管10 ～ 15 min,對兩組患者血透過程中首次使用綜閤徵(First-useSyndrome,FUS)髮生率及體外凝血髮生率進行對比.結果 對照組在560例次透析治療的病人中,共髮生FUS 23例次(4.11％),而實驗組在598例次透析治療的病人中,共髮生FUS 5例次(0.84％).FUS髮生率實驗組明顯低于對照組,兩組比較差異有統計學意義(P＜0.01),而體外凝血髮生率則兩組無明顯改變,差異無統計學意義(P＞0.05).結論 使用患者自體血循管能有效預防血透病人血透過程中首次使用綜閤徵的髮生,且不增加齣血及體外凝血現象風險.
목적 연구사용자체혈순관예방혈투병인수차사용종합정적가행성,제고투석질량、감경환자통고급의료비용.방법 장유지성혈액투석적환자156인공1158례차,안조투석시간분위대조조화실험조.대조조안상규혈투류정조작,실험조재대신적투석기화관로진행상규예충후사용환자자체혈밀폐식순관10 ～ 15 min,대량조환자혈투과정중수차사용종합정(First-useSyndrome,FUS)발생솔급체외응혈발생솔진행대비.결과 대조조재560례차투석치료적병인중,공발생FUS 23례차(4.11％),이실험조재598례차투석치료적병인중,공발생FUS 5례차(0.84％).FUS발생솔실험조명현저우대조조,량조비교차이유통계학의의(P＜0.01),이체외응혈발생솔칙량조무명현개변,차이무통계학의의(P＞0.05).결론 사용환자자체혈순관능유효예방혈투병인혈투과정중수차사용종합정적발생,차불증가출혈급체외응혈현상풍험.
Objective To study the feasibility of using autologous blood circulation pipe syndrome in preventing the first use syndrome (FUS) of hemodialysis patients,improve the quality of dialysis,reduce patients' sufering and medical expenses.Methods The sample pool of 156 maintenance hemodialysis patients with 1158 times of hemodialysis,were divided into control and experimental groups.Normal hemodialysis practices were applied to control group,while 10-15 min of autologous blood circulation pipe after the preshoot of dialyser and pipes practices were applied to experimental group.A comparison of possibility of FUS and in vitro coagulation was conducted between the two groups.Results In the control group with patients given dialysis treatment in 560 cases,there were 23 cases of FUS,the rate was 4.11％,while the experimental group treated dialysis patients in 598 cases,there were 5 cases of FUS,the rate was 0.84％.FUS incidence in the experimental group was significantly lower than that of the control group,the difference was statistically significant (P ＜ 0.01),whereas the incidence of the in vitro coagulation showed no significant change,the difference was not statistically significant (P ＞ 0.05).Conclusion The application of autologous blood circulation pipe is effective in preventing FUS during hemodialysis treatment,meanwhile no bleeding or in vitro coagulation risk increases.
